Trial | NCT01046799  Report issue

Title

Prevention of Hepatitis B Virus Reinfection After Liver Transplantation With Entecavir
Prevention of HBV Reinfection After Liver Transplantation Using Entecavir Monotherapy After Short-term HBIg Administration: A Pilot Study

  • Phase

    Phase 3

  • Study Type

    Interventional

  • Status

    Completed No Results Posted

  • Intervention/Treatment

    entecavir ...

  • Study Participants

    20
The purpose of this study is to determine whether hepatitis B immunoglobin can be discontinued early after hepatitis B virus (HBV) induced liver transplantation and be replaced by the nucleoside analogue entecavir to prevent hepatitis B reinfection.
Study Started
Mar 31
2008
Primary Completion
Jun 30
2014
Study Completion
Oct 31
2014
Last Update
Nov 05
2014
Estimate

Drug Entecavir

Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis

  • Other names: Baraclude

Entecavir Experimental

Criteria 

Inclusion Criteria:

liver transplantation for hepatitis B induced endstage liver disease
absence of coinfection with HIV and HCV
female and male patients >= 18 years of age

Exclusion Criteria:

any evidence of other causes for endstage liver disease
patients that do not fulfill the criteria for liver transplantation
No Results Posted